64320-89-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(hydroxymethyl)pyrrolidin-2-one is used as an intermediate in the preparation of aminopiperidines and related compounds. These compounds act as MCH (melanin-concentrating hormone) receptor modulators, which have potential therapeutic applications in the treatment of various disorders in humans. Specifically, they can be used to address metabolic, feeding, and sexual disorders by modulating the activity of the MCH receptor, thereby influencing the physiological processes associated with these conditions.

Upstream product

• 35309-35-4 5-oxopyrrolidine-3-carboxylic acid methyl ester 
• 181941-94-6 diethyl 2-[1-(diphenylmethyl)azetidin-3-yl]propane-1,3-dioate 
• 183062-93-3 1-Benzhydryl-4-hydroxymethyl-2-oxo-pyrrolidine-3-carboxylic acid 
• 183062-94-4 1-Benzhydryl-4-hydroxymethyl-pyrrolidin-2-one 

Downstream Products

• 64318-92-9 4-(2-tetrahydropyranyl-oxymethyl)-pyrrolidone 
• 945671-51-2 4-(bromomethyl)pyrrolidin-2-one 
• 133749-56-1 1-(4-bromophenyl)-4-(hydroxymethyl)pyrrolidin-2-one 
• 1207840-66-1 5-((pyrrolidin-2-on-4-yl)methylhydroxy)-7-(4-(dimethylamino)-3-methylphenyl)-[1,6]naphthyridine 
• 1207540-19-9 4-[7-(4-morpholin-4-yl-phenyl)-[1,6]naphthyridin-5-yloxymethyl]-pyrrolidin-2-one 

Relevant academic research and scientific papers

Oxazolidinone compounds and its use in medicine (by machine translation)

The invention relates to a benzoxazole compound alkane ketones, and its in the preparation of the prevention and treatment of thromboembolic disease in the application. In particular, the invention relates to the general formula (I)) the compound, among them or their stereoisomers, geometric isomers, tautomers, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug, the variables are defined in the specification. The invention also relates to the general formula (I) compound of formula its stereoisomers, geometric isomers, tautomers, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or salt of a prodrug use as pharmaceuticals, in particular as used for the prevention and treatment of thromboembolic disease of use. (by machine translation)

Pyridine ketone compound and its composition and use thereof (by machine translation)

The invention relates to the field of blood coagulation. In particular, the invention relates to a pyridone compound, or a stereoisomer thereof, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug and pharmaceutical composition containing the compound. The invention also relates to such compounds and pharmaceutical composition preparation method, and they in preparing for the prevention, treatment or alleviation of patient Xa factor relative thromboembolic disease in use. (by machine translation)

Discovery of orally available integrin α5β1 antagonists

Previous research within our laboratories identified the 3-hydroxypyrrolidine scaffold 1 as a new and selective integrin α5β1 inhibitor class which was designed for local administration. Herein the discovery of new orally available integrin α5β1 inhibitor scaffolds for potential systemic treatment is described.

A Straightforward Synthesis of Azetidin-3-ylacetic Acid

The preparation of azetidin-3-ylacetic acid from epichlorohydrin via diethyl 2-[1-(diphenylmethyl)azetidin-3-yl] propane-1,3-dioate is described.